Sequenom Announces Participation At The Piper Jaffray 27th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the Piper Jaffray 27th Annual Healthcare Conference at the Palace Hotel in New York, NY, on December 1, 2015.

Dr. Dirk van den Boom, Interim President and Chief Executive Officer, will participate in a company "fireside chat" to be hosted by Piper Jaffray on Tuesday, December 1, 2015, at 8 a.m. EST. The session is expected to last approximately 30 minutes and will be webcast live and archived for approximately 90 days at the "Invest" section of the Sequenom website,, and at

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT, HerediT UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView, SensiGene® and VisibiliT, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit and follow @SequenomLabs.

SEQUENOM®, HerediT, MaterniT® GENOME,MaterniT21® PLUS, NextView, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.


Logo -


To view the original version on PR Newswire, visit:

SOURCE Sequenom, Inc.

Back to news